Schulman IRB to Open Office in Research Triangle Park, N.C.
Industry-leading IRB secures North Carolina office space to better serve thriving research community
CINCINNATI, OH (April 16, 2015) -- Schulman Associates IRB, Inc., the industry-leading central IRB in customer service and technology, has signed a long-term lease on Laboratory Drive in the heart of Research Triangle Park, North Carolina. The location will house review board and service staff, which will be ideally located to provide high quality reviews and customer service to clients.
CBRE | Raleigh represented Schulman in the deal, while Capital Associates Management, LLC represented the landlord.
"We are pleased to be joining the Triangle community," said Michael Woods, President, CEO and Institutional Official at Schulman. "This office will enable Schulman to be closer to many of our clients and will also help us better serve other research organizations located in this vibrant life sciences community. We look forward to working with our new neighbors and becoming more active in the region in the coming months."
Schulman expects to take occupancy of its RTP office and for the location and its staff to be fully operational later this summer.
About Schulman Associates IRB, Inc.
Schulman Associates IRB has been a leader in the protection of human research participants in the U.S., Puerto Rico and Canada since 1983. Schulman offers thorough, timely IRB review services – including dedicated review capabilities for all phases of research across all therapeutic areas – to clinical trial sponsors, CROs, investigators and institutions. Schulman also provides global consulting services through its joint venture partner Provision Research Compliance Services, offering comprehensive solutions to improve overall quality standards for clinical studies and data integrity, and to maximize the protection of human subjects. Fully accredited by the Association for the Accreditation of Human Research Protection Programs (AAHRPP), Schulman has an unparalleled clean audit history with the Food and Drug Administration (FDA).